Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Scientific presentation

AMP 2021 Corporate Workshop: Single-cell DNA and multi-omics strategies for untangling therapy-resistant mechanisms in oncology

John Lee, M.D., Ph.D., Fred Hutchinson Cancer Research Center & Julia Gouffon, Ph.D., Mission Bio

While great strides have been made in targeted therapies, an improved understanding of therapy resistance is needed to realize the full potential of precision medicine. Bulk sequencing misses the rare events and underlying genetic diversity across cell populations. To improve patient stratification, therapy selection, and disease monitoring, we need insights into clonal architecture, mutation co-occurrence, and immunophenotype within every single cell. Single-cell DNA and multi-omics analyses enable the simultaneous detection of mutation profiles and immunophenotypes in single cells, so you can stratify patients more precisely, signal resistance as it begins, and predict relapse. Speakers will share the strategies they employ to characterize heterogeneity in cancers at the single-cell level.


  • Tractable combinatorial genetics accelerates the functional annotation of cancer genotype-phenotype relationships and the development of clinically relevant disease models
    • Speaker: John Lee, M.D., Ph.D., Assistant Professor, Fred Hutchinson Cancer Research Center
  • Unleashing the Power of Single-cell Multimodal Analysis to Advance Precision Medicine
    • Speaker: Julia Gouffon, Ph.D., Technical Applications Liaison, Mission Bio


Scientific presentation
scTAM-seq: A Novel Method for Profiling DNA Methylation in Single Cells
Michael Scherer, PhD
Agostina Bianchi
Scientific presentation
AML Single-cell Multi-omics MRD (scMRD) and the Horizon of Clinical Utility
Aaron Llanso
AMP 2022 (2022)
Scientific presentation
Molecular Analysis of Acute Myeloid Leukemia in Morphologic Remission
Sanam Loghavi, MD
AMP 2022 (2022)
Scientific presentation
Considerations, Strategies, and Advances in Early Drug Development to Mitigate Clinical Holds and Achieve Successful CGT Outcomes
Azadeh Golipour, PhD, AVROBIO
J. Kelly Ganjei, AmplifyBio
Scott R. Burger, MD, Advanced Cell and Gene Therapy
Matthew Cato